The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Effect of Pravastatin on Outcomes after Cardiac Transplantation
Open accessAbstract
BACKGROUND: Hypercholesterolemia is common after cardiac transplantation and may contribute to the development of coronary vasculopathy. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has been shown to be effective and safe in lowering cholesterol levels after cardiac transplantation. Cell-culture studies using inhibitors of HMG-CoA reductase have suggested an immunosuppressive effect. METHODS: Early after transplantation, we randomly assigned consecutive patients to receive either pravastatin (47 patients) or no HMG-CoA reductase inhibitor (50 patients). RESULTS: Twelve months after transplantation, the pravastatin group had lower mean (+/- SD) cholesterol levels than the control group (193 +/- 36 vs. 248 +/- 49 mg per deciliter, P < 0.001), less frequent cardiac rejection accompanied by hemodynamic compromise (3 vs. 14 patients, P = 0.005), better survival (94 percent vs. 78 percent, P = 0.025), and a lower incidence of coronary vasculopathy in the transplant as determined by angiography and at autopsy (3 vs. 10 patients, P = 0.049). There was no difference between the two groups in the incidence of mild or moderate episodes of cardiac rejection. In a subgroup of study patients, intracoronary ultrasound measurements at base line and one year after transplantation showed less progression in the pravastatin group in maximal intimal thickness (0.11 +/- 0.09 mm, vs. 0.23 +/- 0.16 mm in the control group; P = 0.002) and in the intimal index (0.05 +/- 0.03 vs. 0.10 +/- 0.10, P = 0.031). In a subgroup of patients, the cytotoxicity of natural killer cells was lower in the pravastatin group than in the control group (9.8 percent vs. 22.2 percent specific lysis, P = 0.014). CONCLUSIONS: After cardiac transplantation, pravastatin had beneficial effects on cholesterol levels, the incidence of rejection causing hemodynamic compromise, one-year survival, and the incidence of coronary vasculopathy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although randomized trial data have shown that statins have the potential to improve outcomes in heart transplant patients 195 -197 and renal transplant patients, 198 the amounts of outcome data are not extensive.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [195]
In the citing paper
“Although randomized trial data have shown that statins have the potential to improve outcomes in heart transplant patients 400-402 and renal transplant patients, 403 the amounts of outcome data are not extensive.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [400]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
J Heart Lung Transplant 2021;40(4).
(2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.002 · Cited by 6,665
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Kane, J. P. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450230043027 · Cited by 829
Corpier, C. L. (1988) · JAMA · doi:10.1001/jama.260.2.239 · Cited by 237
Retransplantation for severe accelerated coronary artery disease in heart transplant recipients
Gao, S. Z., Schroeder, J. S., Hunt, S., & Stinson, E. B. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90885-5 · Cited by 189
(1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90858-a · Cited by 182
SHARPLES, L. D., CAINE, N., MULLINS, P., SCOTT, J. P., SOLIS, E., ENGLISH, T. A. H., LARGE, S. R., SCHOFIELD, P. M., & WALLWORK, J. (1991) · Transplantation · doi:10.1097/00007890-199108000-00012 · Cited by 171
Kane, J. P. (1990) · JAMA · doi:10.1001/jama.264.23.3007 · Cited by 169
Eich, D., Ja, T., Dj, K., Hastillo, A., Lower, R. R., Katz, S., Katz, M., & Hess, M. L. (1991) · PubMed · Cited by 142
Research works printed but not linked: 7
- Eich D, 1991, J Heart Lung Transplant, 10, 45
- Blankenhorn DH, 1993, West J Med, 159, 172
- Meiser BM, 1993, Transplant Proc, 25, 2077
- Kobashigawa JA, 1990, Circulation, 82, IV
- Ensley RD, 1991, Transplant Proc, 23, 1130
- Hammond EH, 1992, J Heart Lung Transplant, 11, S111
- Lin H, 1994, J Heart Lung Transplant, 13, 824
Cited by
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
PLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
“In contrast to atherosclerosis, transplant-associated arteriosclerosis is more dependent on immunological mechanisms as opposed to lipid disorders, although hypercholesterolemia exacerbates the immunologic process (82).”
BackgroundACC/AHA guidelines for coronary artery bypass graft surgery
Eagle, K. A., Guyton, R. A., Davidoff, R., Ewy, G. A., Fonger, J., Gardner, T. J., Gott, J. P., Herrmann, H. C., Marlow, R. A., Nugent, W. C., et al. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00389-7 · Cited by 1,995
“Treatment of hyperlipidemia with pravastatin (586) or weekly low density lipoprotein apheresis (587) has been reported to lower the incidence of coronary vasculopathy or even lead to regression.”
BackgroundCostanzo, M. R., Costanzo, M. R., Dipchand, A., Starling, R., Anderson, A., Chan, M., Desai, S., Fedson, S., Fisher, P., Gonzales-Stawinski, G., et al. (2010) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.05.034 · Cited by 1,653
“Three-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (HMG-CoA reductase inhibitors or statins) function as both lipid-lowering and immunomodulating agents.(207) The immunomodulatory mechanisms of statins, which are partially independent of cholesterol-lowering properties may favorably impact survival by redu…”
BackgroundSelf-citation
Metadata
- Authors
- Kobashigawa, J. A., Katznelson, S., Laks, H., Johnson, J. A., Yeatman, L., Wang, X. M., Chia, D., Terasaki, P. I., Sabad, A., Cogert, G. A., Trosian, K., Hamilton, M. A., Moriguchi, J. D., Kawata, N., Hage, A., Drinkwater, D. C., & Stevenson, L. W.
- Affiliations
- University of California, Los Angeles (US)
- Brigham and Women's Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1995-09-07
- Volume
- 333
- Issue
- 10
- Pages
- 621-627
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2338977280
- Cited by
- 1,301
- References
- 22
- Citations by year
- 2026: 11 · 2025: 18 · 2024: 18 · 2023: 15 · 2022: 14 · 2021: 19 · 2020: 27 · 2019: 23 · 2018: 32 · 2017: 28 · 2016: 28 · 2015: 25 · 2014: 49 · 2013: 29 · 2012: 31
- FWCI
- 47.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cardiac and Coronary Surgery Techniques
- Keywords
- pravastatin, heart transplantation, statins, hypercholesterolemia, coronary vasculopathy, immunosuppression, cardiac rejection, survival, intimal thickening, NK cell cytotoxicity, cholesterol lowering
- MeSH terms
- Cholesterol, Coronary Disease, Coronary Vessels, Cytotoxicity, Immunologic, Female, Graft Rejection, Humans, Hypercholesterolemia, Killer Cells, Natural, Male, Middle Aged, Prospective Studies, Incidence, Survival Rate, Heart Transplantation, Pravastatin, Ultrasonography, Interventional
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Pravastatin on Outcomes after Cardiac Transplantation. https://app.cochat.ai/papers/10.1056/nejm199509073331003
- The paper
- Kobashigawa, J. A., Katznelson, S., Laks, H., Johnson, J. A., Yeatman, L., Wang, X. M., Chia, D., Terasaki, P. I., Sabad, A., Cogert, G. A., Trosian, K., Hamilton, M. A., Moriguchi, J. D., Kawata, N., Hage, A., Drinkwater, D. C., & Stevenson, L. W. (1995). Effect of Pravastatin on Outcomes after Cardiac Transplantation. New England Journal of Medicine. https://doi.org/10.1056/nejm199509073331003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.